Privately held Neuraltus Pharmaceuticals Inc. reported Thursday that a confirmatory phase II study of its single candidate, NP-001, that enrolled 138 individuals with amyotrophic lateral sclerosis (ALS) who had elevated levels of systemic inflammation failed to meet its primary and secondary endpoints: change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score and in pulmonary function as measured by slow vital capacity (SVC) readings.